Spacecraft

Aerospace Avionics Market to Reach $111.58 Billion, Globally, by 2032 at 8.9% CAGR: Allied Market Research

Retrieved on: 
Wednesday, March 20, 2024
Statistics, Panasonic Avionics Corporation, PDF, Growth, Communication, Original equipment manufacturer, EFVS, Airbus, Elbit Systems, Research, STC, Boeing, Aviation, Universal Avionics, Spacecraft, WAM, OEM, 737NG, Thales Group, System, Radar, Safety, Collins Aerospace, Chart, Growth hacking, Table, Airline

PORTLAND, Ore., March 20, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Aerospace Avionics Market, by Subsystem (Flight Management Systems, Flight Control Systems, Health Monitoring Systems, Electrical & Emergency Systems and Communication, Navigation, and Surveillance Systems), Platform (Military Aviation, Commercial Aviation, General Aviation, and Special Mission Aviation), Fit (Retrofit and Forward Fit), and End-Use (OEM and Aftermarket): Global Opportunity Analysis and Industry Forecast, 2022–2032". the global aerospace avionics market size was valued at $48.74 billion in 2022, and is projected to reach $111.58 billion by 2032, registering a CAGR of 8.9% from 2023 to 2032.

Key Points: 
  • Increase in traffic densities, increase in need to utilize RF spectrum, and improved safety nets have elevated the demand for surveillance systems.
  • This upgrade replaces legacy Pro Line 4 avionics with cutting-edge displays and synthetic vision, addressing obsolescence issues, improving operational efficiency, and enhancing safety.
  • Rigorous safety standards and a growing emphasis on aviation cybersecurity are prompting investments in avionics technology, thus driving the market.
  • The aerospace avionics market analysis spans across more than 16 countries, offering a detailed breakdown of each country's value ($million) from 2022 to 2032.

NASA's Curious Universe Podcast Unveils New Sun + Eclipse Series

Retrieved on: 
Tuesday, March 19, 2024
Eclipse, Universe, Sun, Science, Explosion, Apple Podcasts, Research, Goddard Space Flight Center, Google Podcasts, Optical phenomena, Spacecraft, NASA, Field line, Multimedia, Communications satellite

Ahead of the total solar eclipse in April, NASA's Sun + Eclipse Series will focus on the sphere full of swirling magnetic fields and explosions of hot gases.

Key Points: 
  • Ahead of the total solar eclipse in April, NASA's Sun + Eclipse Series will focus on the sphere full of swirling magnetic fields and explosions of hot gases.
  • The series is part of NASA's Curious Universe podcast.
  • NASA's Sun + Eclipse Series is now available on Spotify, Apple Podcasts , Google Podcasts , and Soundcloud .
  • Curious Universe is written and produced by a team at the agency's Goddard Space Flight Center in Greenbelt, Maryland.

NASA to Send Research to Station Aboard 30th SpaceX Resupply Mission

Retrieved on: 
Friday, March 15, 2024
Physics, CSA, Metabolism, Lifting, Research, International Space Station, Blog, Astrobee, EDT, Television, News, Food, Spacecraft, Canadian Space Agency, NASA, Kennedy Space Center, Harmony, SpaceX, SpaceX Dragon, NASA TV, Dragon, Communications satellite

WASHINGTON, March 15, 2024 /PRNewswire/ -- New research and technology demonstrations for NASA are set to launch aboard the agency's SpaceX 30th commercial resupply services mission to the International Space Station.

Key Points: 
  • WASHINGTON, March 15, 2024 /PRNewswire/ -- New research and technology demonstrations for NASA are set to launch aboard the agency's SpaceX 30th commercial resupply services mission to the International Space Station.
  • Live launch coverage will air on NASA+ , NASA Television, the NASA app , and the agency's website, with prelaunch events starting Tuesday, March 19.
  • NASA and its partners will send studies aboard the mission on plant metabolism in space and a set of new sensors for free-flying Astrobee robots to provide 3D mapping capabilities.
  • On launch day, live coverage of the launch without NASA Television commentary will be carried on the NASA Television media channel.

Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

Retrieved on: 
Thursday, March 14, 2024
Bioreactor, Control, TFF, Growth, PROTAC, LPH, DCAT, CGMP, CMC, EMA, Spacecraft, MD, Senior, Quality assurance, US FDA, Unit, Biocon, Perfusion, Fine chemical

BANGALORE, India, March 14, 2024 /PRNewswire/ -- At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International, a global contract research, development and manufacturing organization (CRDMO), will announce that its newly upgraded biologics facility - Unit 3 - would be operational for clinical and commercial supply in the second half of 2024.

Key Points: 
  • The facility will be available for biotech and pharma customers seeking drug substance and drug product contract manufacturing.
  • The Company also has a microbial cGMP facility and a mammalian cell manufacturing facility to extend end-to-end Chemistry, Manufacturing and Control (CMC) development solutions for its global clients.
  • The integration of chromatography systems streamlines the purification processes and enhances the overall efficiency of biologics manufacturing.
  • In total Unit 3 will have around 100 staff for Quality Assurance and Manufacturing, part of Syngene's 600-strong team across its biologics manufacturing services and supporting specialist functions.

Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

Retrieved on: 
Thursday, March 14, 2024
Bioreactor, Control, TFF, Growth, PROTAC, LPH, DCAT, CGMP, CMC, EMA, Spacecraft, MD, Senior, Quality assurance, US FDA, Unit, Biocon, Perfusion, Fine chemical

BANGALORE, India, March 14, 2024 /PRNewswire/ -- At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International, a global contract research, development and manufacturing organization (CRDMO), will announce that its newly upgraded biologics facility - Unit 3 - would be operational for clinical and commercial supply in the second half of 2024.

Key Points: 
  • The facility will be available for biotech and pharma customers seeking drug substance and drug product contract manufacturing.
  • The Company also has a microbial cGMP facility and a mammalian cell manufacturing facility to extend end-to-end Chemistry, Manufacturing and Control (CMC) development solutions for its global clients.
  • The integration of chromatography systems streamlines the purification processes and enhances the overall efficiency of biologics manufacturing.
  • In total Unit 3 will have around 100 staff for Quality Assurance and Manufacturing, part of Syngene's 600-strong team across its biologics manufacturing services and supporting specialist functions.

Europe Sub-Orbital Testing Services Industry Research 2022-2032: Start-Ups and Investment Scenario, Commercial Sub-Orbital Launch Sites and Spaceports, On-going NASA Programs

Retrieved on: 
Wednesday, March 13, 2024
European Space Agency, Benchmarking, Growth, ESA, Airbus, Research, Commercial, Spacecraft, Australian Space Agency, Investment, COTS, OneWeb, Government, Communications satellite

Increased demand from a variety of end users is driving investments in sub-orbital launch vehicle platforms in the European sub-orbital testing services market.

Key Points: 
  • Increased demand from a variety of end users is driving investments in sub-orbital launch vehicle platforms in the European sub-orbital testing services market.
  • The favored strategy for the companies has been contracted to strengthen their position in the Europe sub-orbital testing services market.
  • Competitive Strategy: Key players in the Europe sub-orbital testing services market analyzed and profiled in the study involve sub-orbital testing service providers.
  • What is the current and future revenue scenario of the Europe sub-orbital testing services market?

Lung Cancer Research Foundation Announces Research Grant Awards

Retrieved on: 
Tuesday, March 12, 2024
Spacecraft, Lung cancer, Cancer, Patient, ADC, Biomarker, Research, AstraZeneca, Daiichi Sankyo, Fine chemical

NEW YORK, March 12, 2024 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) has announced three research grant awards funded by Daiichi Sankyo and AstraZeneca, totaling $810,000, focused on further developing the understanding of the proposed mechanism of action of antibody drug conjugates (ADCs), exploring biomarkers and blood-based biomarkers for the primary and acquired resistance mechanisms to TROP2- or HER2-directed ADCs and exploring the use of ADCs in lung cancer types beyond non-small cell lung cancer (NSCLC).

Key Points: 
  • NEW YORK, March 12, 2024 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) has announced three research grant awards funded by Daiichi Sankyo and AstraZeneca, totaling $810,000, focused on further developing the understanding of the proposed mechanism of action of antibody drug conjugates (ADCs), exploring biomarkers and blood-based biomarkers for the primary and acquired resistance mechanisms to TROP2- or HER2-directed ADCs and exploring the use of ADCs in lung cancer types beyond non-small cell lung cancer (NSCLC).
  • ADCs are designed to specifically target cancer cells and selectively deliver a highly potent payload, which may limit damage to healthy cells.
  • "LCRF is honored to continue its long legacy of identifying and supporting outstanding lung cancer research projects over the years, and we are excited to present these grants made possible by this research collaboration," said Dr. Antoinette Wozniak, LCRF's chief scientific officer.
  • "The study of ADCs is an exciting development in lung cancer research with considerable promise for increased positive outcomes for patients."

Comsat Architects and Ubotica Technologies Join Forces to Bring AI to Space

Retrieved on: 
Tuesday, March 12, 2024
LEO, Algorithm, Communication, Intelligence, Partnership, AI, Spacecraft, NASA, Artificial intelligence, Orbit, Communications satellite

Together, Comsat Architects and Ubotica will integrate Artificial Intelligence (AI) technologies into the combination of communication and Earth observation on small satellites in low Earth orbits to unlock the opportunity for Live Earth Intelligence.

Key Points: 
  • Together, Comsat Architects and Ubotica will integrate Artificial Intelligence (AI) technologies into the combination of communication and Earth observation on small satellites in low Earth orbits to unlock the opportunity for Live Earth Intelligence.
  • Comsat Architects provides services in space communication analysis, advanced software, and aerospace technologies to civil and commercial sectors.
  • Comsat Architects specializes in space connectivity for spacecraft in LEO orbit, and the infusion of AI/ML technologies into various aspects of data delivery.
  • "This strategic collaboration signifies a major milestone in harnessing the combined expertise of Comsat Architects and Ubotica to advance AI technologies in space systems," said Kul Bhasin, Ph.D., CEO of Comsat Architects.

Splashdown! NASA's SpaceX Crew-7 Finishes Mission, Returns to Earth

Retrieved on: 
Tuesday, March 12, 2024
SpaceX Crew-7, Commercial Crew Program, Electricity, European Space Agency, JAXA, Rotation, ESA, Science, SpaceX Crew-3, International Space Station, EDT, Transport, Johnson Space Center, Food, SpaceX Crew-5, Spacecraft, Moon, NASA, Kennedy Space Center, Harmony, Multimedia, SpaceX, Orbit, Communications satellite

Teams aboard SpaceX recovery vessels retrieved the spacecraft and its crew.

Key Points: 
  • Teams aboard SpaceX recovery vessels retrieved the spacecraft and its crew.
  • "After more than six months aboard the International Space Station, NASA's SpaceX Crew-7 has safely returned home," said NASA Administrator Bill Nelson.
  • Moghbeli, Mogensen, Furukawa, and Borisov traveled 84,434,094 miles during their mission, spent 197 days aboard the space station, and completed 3,184 orbits around Earth.
  • The goal of NASA's Commercial Crew Program is safe, reliable, and cost-effective transportation to and from the International Space Station and low Earth orbit.

Shasqi Appoints Travis Biechele, Ph.D. as VP of Research to Lead Pipeline Development

Retrieved on: 
Monday, March 11, 2024
Pharmacology, Therapeutic index, Seagen, SAN, Patient, University, Spacecraft, MD, Neoplasm, CAPAC, ADC, Shasqi, Click chemistry, Pharmaceutical industry

SAN FRANCISCO, March 11, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced that it has appointed Travis Biechele, Ph.D. as VP of Research.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced that it has appointed Travis Biechele, Ph.D. as VP of Research.
  • Biechele has over two decades of experience in oncology research, with a focus on developing antibody-drug conjugates (ADCs), with both Seagen (now Pfizer) and Merck.
  • Shasqi's pipeline is composed of a range of tumor-targeted activators against validated antigen targets that are combined with protodrugs based on a range of validated payloads.
  • Prior to Merck, Biechele spent 10 years at Seagen (now Pfizer), where he played a pivotal role in the development of ADC technology.